Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management
(2021). Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management. EKB Journal Management System, 1(1), -. doi: 10.21608/esdlj.2021.455584
. "Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management". EKB Journal Management System, 1, 1, 2021, -. doi: 10.21608/esdlj.2021.455584
(2021). 'Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management', EKB Journal Management System, 1(1), pp. -. doi: 10.21608/esdlj.2021.455584
Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management. EKB Journal Management System, 2021; 1(1): -. doi: 10.21608/esdlj.2021.455584

Statins Induced Myopathy Among Diabetes with Peripheral Neuropathy: Incidence, Etiology and Management

Egyptian Society of Diabetes and Lipidology Journal
Volume 1, Issue 1, October 2021    PDF (76.32 K)
Document Type: Abstracts
DOI: 10.21608/esdlj.2021.455584
Abstract
Statins-induced myopathy and neuropathy are more pronounced in diabetes who suffer from peripheral neuropathy. Lipid-lowering drugs are indispensable for cardiovascular protection in diabetes. Myopathy is the principal reason for statins non non-adherence and /or discontinuation. This study aims to answer what  is the rate of incidence does  statin-induced  undesirable effects myopathy affecting  diabetes, especially those with complications such as neuropathy which  aggravates  it,  
etiology and best management (and alternatives ) to profit statins' benefits, overcoming their risks. 
Statistics
Article View: 23
PDF Download: 4